证券代码：300534 证券简称：陇神戎发 公告编号：2025-062 甘肃陇神戎发药业股份有限公司 2025年第四次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东会未出现否决议案的情形； 2.本次股东会不涉及变更以往股东会已通过的决议的情形。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间： 出席本次股东会现场会议和网络投票的股东及股东授权委托代表共 165 人， （1）现场会议召开时间：2025 年 9 月 9 日下午 14:30 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025年9月9日9:15—9:25，9:30—11:30和13:00—15:00；通过深圳证券交易所 互联网投票系统进行网络投票的时间为2025年9月9日9:15—15:00期间的任意时 间。 2.现场会议地点：甘肃省兰州市榆中县定远镇国防路 10 号公司六楼会议室 3.会议召开方式：本次股东会采取现场投票与网络投票相结合的方式召开 4.会议召集人：公司董事会 5.会议主持人：董事长康永红先生 6.本 ...

北京德恒（兰州）律师事务所 关于甘肃陇神戎发药业股份有限公司 2025 年第四次临时股东会 之 法律意见书 甘肃省兰州市城关区雁园路 601 号甘肃省商会大厦 A 座 15 层 电话：（0931）8260111 邮编：730030 关于甘肃陇神戎发药业股份有限公司 2025 年第四次临时股东会法律意见书 北京德恒（兰州）律师事务所 关于甘肃陇神戎发药业股份有限公司 2025 年第四次临时股东会之 法律意见书 致：甘肃陇神戎发药业股份有限公司 本法律意见书仅供贵公司本次股东会相关事项的合法性之目的使用，不得用 于其他任何目的或用途。 基于此，本所律师依据《证券法》《律师事务所从事证券法律业务管理办法》 1 关于甘肃陇神戎发药业股份有限公司 2025 年第四次临时股东会法律意见书 和《律师事务所证券法律业务执业规则》等规定，严格履行了法定职责，遵循了 勤勉尽责和诚实信用原则，进行了充分的核查验证，保证本法律意见书所认定的 事实真实、准确、完整，所发表的结论性意见合法、准确，不存在虚假记载、误 导性陈述或者重大遗漏，并承担相应法律责任。现出具法律意见如下： 一、本次股东会的召集程序 北京德恒（兰州）律师事务所（以下 ...

公司发布的半年报数据显示，上半年公司共实现营业收入4.96亿元，同比下降8.21%，实现净利润 2795.61万元，同比增长27.48%，基本每股收益为0.0922元，加权平均净资产收益率4.08%。（数据宝） （文章来源：证券时报网） 陇神戎发9月3日披露，截至8月31日公司股东户数为28030户，较上期（8月20日）减少2181户，环比降 幅为7.22%。这已是该公司股东户数连续第2期下降。 证券时报·数据宝统计，截至发稿，陇神戎发收盘价为9.98元，下跌2.06%，本期筹码集中以来股价累计 下跌10.09%。具体到各交易日，2次上涨，8次下跌。 ...

Core Viewpoint - The company, Longshen Rongfa, reported that as of August 29, 2025, the number of shareholders reached 28,030 [2] Summary by Relevant Sections - Shareholder Information - The total number of shareholders for the company is 28,030 as of the specified date [2]

Group 1 - The core idea of the news is the launch of ten innovative policy reform pilot projects in Gansu Province aimed at stimulating innovation and creating a better technological innovation ecosystem to support the establishment of a regional technology innovation and transformation base [2][6] - The Gansu Provincial Innovation Policy Reform Pilot Work aims to enhance the effectiveness of technological breakthroughs by organizing collaboration among enterprises, universities, and research institutions [2][4] - The Gansu High-tech Zone has developed a model focusing on collaborative development in the biopharmaceutical industry, targeting areas such as gene and cell therapy, AI+pharmaceuticals, and new vaccine development [2][3] Group 2 - The Gansu Province aims to achieve a total biopharmaceutical output value exceeding 30 billion yuan within a year, with plans to develop 3-5 generic drugs or biological products and 2-3 innovative drugs [3] - A technology investment conference was held, featuring major scientific contributions and technology demands from various sectors, including new energy, new materials, and biomedicine [4] - The Gansu Province has successfully signed contracts for 30 major technology resource introduction projects, demonstrating active engagement in technology investment and collaboration [4] Group 3 - The pilot reform of talent evaluation in Gansu Province focuses on establishing a new evaluation system based on innovation capability, effectiveness, and contribution [5] - The Gansu Provincial Science and Technology Information Research Institute has categorized scientific talents into four types, creating tailored growth paths to promote meritocracy [5] - The pilot program has shown significant results, boosting confidence in further reforms and the expansion of pilot projects across the province [6]

Group 1 - The core viewpoint of the news is that Gansu Longshen Rongfa Pharmaceutical Co., Ltd. has reported a decrease in total operating revenue while showing an increase in net profit for the first half of 2025 [1] - As of August 25, 2025, the company's stock price closed at 10.97 yuan, down 0.99%, with a turnover rate of 6.15% and a trading volume of 185,600 hands, amounting to 203 million yuan [1] - The company's latest financial results show total operating revenue of 496 million yuan, a year-on-year decrease of 8.21%, while net profit attributable to shareholders reached 27.96 million yuan, a year-on-year increase of 27.48% [1] Group 2 - The company has a current ratio of 1.546, a quick ratio of 1.238, and a debt-to-asset ratio of 44.22% [1] - Gansu Longshen Rongfa has made investments in 5 enterprises and participated in 2,054 bidding projects [2] - The company holds 17 trademark registrations and 46 patents, along with 160 administrative licenses [2]

Core Viewpoint - Longshen Rongfa (300534) reported a net profit increase of 27.48% for the first half of 2025, despite a decline in total revenue by 8.21% compared to the previous year [1] Financial Performance - Total revenue for the first half of 2025 was 496 million yuan, down from 541 million yuan in 2024, representing an 8.21% decrease [1] - Net profit attributable to shareholders reached 27.96 million yuan, up from 21.93 million yuan in 2024, marking a 27.48% increase [1] - The gross profit margin decreased to 66.19%, down 13.38% year-on-year, while the net profit margin increased to 8.25%, up 18.99% [1] - Total operating expenses (selling, administrative, and financial) amounted to 248 million yuan, accounting for 50.05% of revenue, a decrease of 20.43% [1] - Earnings per share rose to 0.09 yuan, a 27.52% increase from 0.07 yuan in 2024 [1] Cash Flow and Debt - Operating cash flow per share was -0.21 yuan, a significant decrease of 129.82% year-on-year, attributed to reduced sales collections and increased payments related to operating activities [1][3] - The company’s monetary funds decreased by 39.05% to 215 million yuan, while accounts receivable increased by 27.52% to 235 million yuan [1] Business Model and Product Development - The company relies heavily on research and marketing to drive performance, with a historical return on invested capital (ROIC) of 5.51%, indicating average capital returns [3] - Longshen Rongfa is focused on the development of its main products, including the unique "Yuanhu Zhitong Dwan," which has been recognized for its efficacy in treating various types of pain [5][6] - The company is actively pursuing the second development of major products and enhancing its technological barriers through various research projects [6] Market Strategy and Future Outlook - The company is optimistic about the health sector and is expanding its product offerings in this area, including various health products [7] - It aims to leverage its advantages in the traditional Chinese medicine industry, supported by recent government policies promoting the sector [9] - The company plans to enhance its quality management system and increase R&D investments to develop more high-quality products [9]

Group 1 - The company announced the approval of multiple proposals during the 20th meeting of the fifth board of directors, including adjustments to the expected daily related transactions for the year 2025 [2]

Core Viewpoint - The company Longshen Rongfa announced a cash dividend distribution plan for the first half of 2025, proposing a distribution of 0.2 yuan per 10 shares, totaling approximately 6.07 million yuan, which represents 21.70% of its net profit [1][4]. Company Distribution History - The company has a history of cash distributions since its listing, with the latest plan being the eighth distribution. The cash distribution amounts and dividend yields for previous distributions are as follows: - 2025.06.30: 0.06 billion yuan, 0.21% yield - 2024.12.31: 0.06 billion yuan, 0.22% yield - 2024.06.30: 0.06 billion yuan, 0.23% yield - 2023.12.31: 0.06 billion yuan, 0.20% yield - 2019.12.31: 0.03 billion yuan, 0.15% yield - 2018.12.31: 0.03 billion yuan, 0.11% yield - 2017.12.31: 0.04 billion yuan, 0.05% yield - 2016.12.31: 0.09 billion yuan, 0.14% yield [2]. Financial Performance - For the first half of 2025, the company reported total revenue of 496 million yuan, a year-on-year decrease of 8.21%. However, net profit reached 27.96 million yuan, reflecting a year-on-year increase of 27.48%. The basic earnings per share were 0.0922 yuan, with a weighted average return on equity of 4.08% [2]. Market Position - In terms of cash distribution within the pharmaceutical and biotechnology sector, Longshen Rongfa's cash distribution of 6.07 million yuan ranks lower compared to its peers. For instance, WuXi AppTec led the sector with a distribution of 1.003 billion yuan, followed by Dong-E E-Jiao and China Resources Sanjiu with distributions of 817.21 million yuan and 751.31 million yuan, respectively [3].

Core Viewpoint - Longshen Rongfa (300534.SZ) reported a steady growth in revenue and net profit for the first half of 2025, demonstrating resilience in a challenging economic environment and a competitive pharmaceutical industry [1] Financial Performance - The company achieved an operating income of 496 million yuan and a net profit attributable to shareholders of 27.96 million yuan, representing a year-on-year increase of 27.48% [1] - The net profit after deducting non-recurring gains and losses reached 30.49 million yuan, up 39.93% compared to the previous year [1] Product and Market Development - Longshen Rongfa focuses on its core pharmaceutical business, enhancing its marketing system and brand building, which has led to increased hospital coverage for its key products [1] - The core products, Yuanhu Zhitong Diban and Xuanfei Zhiso Heji, covered 2,858 and 2,299 hospitals respectively, with coverage rates increasing to 19.39% and 15.56% [1] - Revenue from the drop pill products grew by 31.22% year-on-year, indicating effective market promotion [1] Product Recognition - Yuanhu Zhitong Diban and Xuanfei Zhiso Heji received multiple industry awards for their clinical efficacy and brand recognition [2] - Xuanfei Zhiso Heji ranked 7th in the "2024 China Innovative Drug Sales Enterprise Ranking (Traditional Chinese Medicine) TOP20" [2] - Yuanhu Zhitong Diban was listed among the top 20 brands in sales for traditional Chinese medicine pills in public medical institutions [2] Project Development - The company made significant progress in capacity enhancement and technology upgrades, including the acquisition of 70% of the Innovative Research Institute [3] - The production line upgrade for Xuanfei Zhiso Heji has been completed and passed GMP compliance checks, ready for production [3] - The construction and registration of a new production line for blood dialysis concentrate is underway, expected to become a new growth point [3] R&D Innovation - Longshen Rongfa established a technical center laboratory with Puan Pharmaceutical to facilitate the industrialization of R&D results [4] - Ongoing research includes real-world studies for Xuanfei Zhiso Heji and new formulations for Yuanhu Zhitong Diban [4] - The company collaborates with Lanzhou University for health food R&D, with several products launched through dual-channel marketing [4] Investor Returns and Social Responsibility - The company plans to distribute a cash dividend of 0.2 yuan per 10 shares to all shareholders for the first half of 2025 [4] - Longshen Rongfa has been recognized as a "green factory" and included in the list of high-tech, high-growth enterprises in Gansu Province [4]